CD40LG and glioblastoma: Anti-GBM patients with positive P2-IgM and P4-IgM had a lower rate of positive ANCA (P2-IgM: 0 vs. 40%, P<0.001; P4-IgM: 7.8% vs. 52%, P<0.001), respectively.